Scholar Rock is trading at $46.23, down 4.33%, with no clear company-specific catalyst identified for the October 1 decline.

  • No clear company-specific announcement explaining the decline appeared in the search results. The FDA pregnancy-safety study and fracture-reporting requirements were reported in mid-September and do not establish a new catalyst for this session.
  • The supplied market indices are nearly flat, and available evidence does not show Scholar Rock tracking a significant broader-market move. The cause of the decline remains unclear.